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Abstract 

Background: Multiple reforms have been introduced in the Republic of Srpska to enhance prescribing efficiency. Objective: Assess their influence on utilisation and expenditure on PPIs, statins and the renin-angiotensin inhibitor drugs. Secondly, assess whether the Republic can obtain low prices for generics. Thirdly, suggest additional reforms that could be introduced. Methods: Observational study of all ambulatory care patients between 2003 and 2010. Defined daily doses (DDD) and DDDs/TID used for measuring changes in utilization. Reimbursed expenditure used as health insurance perspective. Results: Increasing utilisation in all three classes. Utilisation of ARBs principallyb limited by prescribing restrictions. Reimbursed expenditure/ DDD in all three classes decreased by up to 82% in 2010 versus 2004, appreciably improving prescribing efficiency for the statins. Increased utilisation of esomeprazole at higher reimbursed expenditure/ DDD, and similarly ACEI combinations at higher expenditure versus single drugs, limited the ability to fully capitalise on these reductions. Conclusion: Multiple measures helped lower expenditure/ DDD, providing hope to countries with small populations.  Further measures are planned.
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Introduction

Pharmaceutical expenditure has been growing across Europe, driven by well known factors including ageing populations, rising patient expectations and the continued launch of new expensive drugs [1-7]. As a result, pharmaceutical expenditure is now the largest or equalling the largest component in ambulatory care across countries [1-5,7,8]. This has resulted in multiple supply and demand side measures being introduced across Europe to counterbalance rising costs that challenge the European ideals of comprehensive and equitable healthcare. Reforms and initiatives include reference pricing for molecules and classes with patients covering the additional costs themselves for a more expensive product than the referenced one, compulsory price cuts, compulsory generic substitution, educational initiatives including guidelines, formularies and benchmarking of prescribing habits among physicians, prescribing targets, financial incentives as well as prescribing restrictions [1-5,7-11]. The Republic of Srpska is no different.

The Republic is one of the two constitutive entities of Bosnia and Herzegovina, accounting for 49% of the land mass of the country with an estimated population of 1.43 million inhabitants [12,13]. There was a steady increase in Gross Domestic Product (GDP) in the Republic up till 2007, which subsequently fell following the financial crisis. GDP has now increased, resulting in GDP per capita increasing from €979 in 2000 to €2960 in 2010 [12,13,101]. Expenditure on public health has similarly increased from 3.1% of GDP in 2005 to 5.9 % in 2010, with public pharmaceutical expenditure per capita  increasing form 28€ in 2005 to 75€ in 2010 [12,13-16].

The Republic of Srpska has executive and legislative functional responsibilities covering health care policies. The authority for providing healthcare is centralised, with the Ministry of Health and Social Welfare responsible for planning, regulation and management functions [12]. The Health Insurance Fund (HIF) provides health insurance coverage for the population. It operates on the basis of solidarity and mutuality, mirroring other European countries. The HIF is legally responsible for collecting and allocating finances to health care providers [12].

With respect to pharmaceuticals, the national medicines policy adopted in 2006 had as its objective ‘the need to ensure access to effective, safe and quality medicines, made available in a rational and cost-effective manner to the whole population ’ [12].  As part of this, there is a positive list of drugs published in the Official Gazette and reimbursed by HIF, collated by Anatomical Therapeutic Chemical (ATC) classification [12, 102]. This was a single list until May 2008. After this, the List was divided into two - List A and List B. List A is the basic list of drugs including those for chronic diseases such as epilepsy, diabetes, cardiovascular diseases as well as chronic psychiatric conditions. Drugs are covered 100% up to the reference price level for patients exempt from the co-payment; otherwise there is a 10% co-payment of the reimbursed reference price combined with an additional co-payment if pertinent for a more expensive molecule than the current referenced price molecule [12]. List B is a complementary list with a mandatory 50% co-payment. This typically includes second line and/or more expensive treatments. Alongside this, drugs for severe diseases such as cancer, HIV/ AIDS and multiple sclerosis are dispensed from hospital pharmacists and are fully reimbursed [12]. All manufacturers with a market authorisation for molecules (ATC Level 5, i.e. specific drugs) already on the List are now automatically included in the HIF price list, which is periodically updated.  This approach enables equality of access for all manufacturers, process transparency as well as patient choice. 

There have been recent changes to the pricing of generics in the Republic of Srpska. Until 2006, HIF's reference price for a molecule was set at the price dictated by each manufacturer. At the beginning of 2006, the reference price for the molecule (ATC Level 5) became the current median price for molecule among those currently reimbursed and on the market in the Republic of Srpska.  From the beginning of May 2008, the reference price reimbursed by HIF became the lowest price for the molecule with patients required to cover the difference themselves for a more expensive molecule than the current reference price. As a result, market forces should drive down generic prices as different generics receive market authorisation with the different manufacturers trying to become the referenced price molecule to reduce patient co-payments [4]. This is different to the procurement process in hospitals, and also different to the reimbursement and pricing negotiations that typically take place for new drugs in the Republic of Srpska and elsewhere in Europe [1-4,12]. VAT at 17% is included for drugs with the same International Non-proprietary Name (INN) (ATC level 5), which is typically the generic drug price [103]. 

Table 1 contains details of the demand side measures introduced into the Republic in recent years to enhance prescribing efficiency. These have been collated under the 4Es – Education, Engineering, Economics and Enforcement to enhance comparisons across countries [5,7,11,17].



Table 1 – Demand side measures introduced in the Republic of Srpska in recent years [12, 34,44-47]

Education	Prescribing guidelines via drug formularies or standard treatment guidelinesPrior to 2009, a Drug Formulary was published annually by the Republic of Srpska Drug Regulatory Agency. After 2009, a Medicines and Medical Devices Agency was established in Bosnia and Herzegovina (B & H) with the B&H Drug Formulary available and updated annually (the Medicines and Medical Devices Agency is responsible for evaluating medicines for marketing authorization within B & BH including the Republic of Srpska)Standard Treatment Guidelines for a number of diseases in ambulatory care have been available since 2004. These were updated in 2009 along with the publication of additional treatment guidelines. These include those for acid-related stomach disorders including functional dyspepsia and peptic ulceration, hyperlipidaemia and hypertension Therapeutic recommendations to be written by INN (International Non-proprietary Name) – encouraged in the future through the instigation of e-prescribingBoth formulary and the guidelines available as a hard copy and on a CD
Engineering	Pharmacists allowed to dispense a generic drug in place of the originator if no complaints from patientsProfessionally pharmacists are obliged to offer a patient the cheapest product when multiple sourced products are available, which is usually a genericHealth Institutions given a drug budget each year based on a weighted capitation formula, which is built into the annual contract between HIF and each institution. Each institution is monitored for its financial performance alongside its rational use of drugs according to the Positive List and Standard Treatment guidelines, with a financial risk for any over budget situation (Economics)
Economics	HIF can withdraw a code given to the physician (temporary or permanent depending on the situation) if his/her prescribing costs exceeds or continue to be excessive following input from HIF personnel. As a result, physicians would be unable to prescribe drugs from the positive list leading to 100% co-paymentPhysicians encouraged through financial measures to prescribe by INNPatients pay the difference for a more expensive product than the current reference price (ATC level 5) in addition to the current co-payments for products in List A and BPatients pay the full cost of their medicines in the pharmacy (100% co-pay) if the indication for the prescribed medicine is different from those permitted by HIF (below - Enforcement), there is a missing opinion or other missing details on the prescription (if identified); otherwise they must return to the doctor for a revised prescription to limit their co-payment 
Enforcement	Prescribing according to defined diagnoses for target drugs and indicationsOnly permitted diagnoses are recognized by the HIF Information system. As a result, all prescriptions with different diagnose than permitted for the drug will be automatically rejected and returned back to the pharmacy. Prescriptions with missing specialist’s recommendation on the back will also be returned to the pharmacyIn both cases, the invoice from the pharmacist will be reduced by the drug costsConsequently, it is in the interest of the pharmacist to check prescriptions against the diagnosis/ requested data and alert the patient if needed else they could loose income

The primary objective of this paper is to assess the influence of multiple supply and demand side measures introduced in the Republic of Srpska in recent years to increase prescribing efficiency. This will be achieved by analysing the utilisation and expenditure patterns for three high volume classes over time. These are the proton pump inhibitors (PPIs), the HMG CoA reductase inhibitors (statins) and the renin-angiotensin inhibiting drugs – Angiotensin Converting Enzyme Inhibitors (ACEIs) and the Angiotensin Receptor Blockers (ARBs). Prescribing efficiency is defined in this context as utilisation growing more rapidly than expenditure in each of the three classes, where the drugs are seen as essential similar for all or nearly all patients. Health authorities and health insurance agencies typically view all PPIs as having similar effectiveness [4,5,9-11, 18-21]. They also believe all statins are essentially similar for the vast majority of patients [4,5,9,11,18-22]. This was confirmed in a recent ecological study, which showed similar outcomes in terms of the subsequent impact of drug treatment on lipid levels whether patients were prescribed formulary drugs (including generic simvastatin) versus non-formulary drugs, which included patent protected statins [23]. Studies have also shown that patients can be successfully switched between atorvastatin and simvastatin without compromising care [10,19,20,22,24]. Finally, health authorities and health insurance companies believe that the effectiveness of ACEIs and ARBs are similar [7,9, 25,26]. Prospective clinical trials have shown that a dry cough only occurs in approximately 10% of patients prescribed ACEIs, and only 2% to 3% of patients on ACEIs discontinued their drug due to a dry cough in clinical trials [27,28]. Consequently, again overall there appears to be no appreciable difference between ACEIs and ARBs in the vast majority of patients.

Secondly, assess whether the relatively small population of the Republic of Srpska prevents them from obtaining low prices for generics. We believe this is important as a recent editorial in a leading journal stated 'smaller countries reported difficulties in negotiating with the drug industry'  [29,30], although this was not the case in Lithuania [31]. This will be achieved by appraising the price reductions that are seen in the various classes over time, as well as by comparing reimbursed expenditure for generic omeprazole, simvastatin and ACEIs with a mixture of European countries with both small and large populations. 

Thirdly, suggest additional reforms that could potentially be introduced in the Republic to further enhance prescribing efficiency.

We would expect increased utilisation of all three classes over time with ageing populations and an increased number of drugs on the reimbursement list [12]. We would also expect to see increased prescribing efficiency following successive reforms to reduce reimbursed prices for multiple sourced products. Finally, we would also expect to find lower utilisation of PPIs and statins in the Republic of Srpska than seen among Western European countries in view of current co-payment rates and prescribing restrictions.

Methodology

This is an observational study of all ambulatory care patients included in the compulsory health insurance system in the Republic of Srpska. Prescription data was obtained from the HIFelectronic database, with the study years depending on the Positive List updates. The HIF database provides the complete reimbursed prescription medication history of all patients, diagnosis (according IDC-10), physician prescriber as well as the pharmacy where the prescription was dispensed in the Republic for the years documented. The robustness and validity of the database is assured by regular monitoring and auditing of drugs dispensed from HIF contracted pharmacies. Currently there are no parallel imported products within the Republic of Srpska.

The study included all patients dispensed at least one reimbursed prescription for any PPI (ATC – Anatomical Therapeutic Chemical Classification - group A02BC), statin (C10AA), ACEI alone or in combination (C09AA, C09BA) or ARB alone or in combination (C09CA or C09DA), between 2003 and 2010 [102]. Defined daily doses (DDD) as well as DDDs/1000 inhabitants per day  (DDD/TID) were used for measuring drug utilization. DDDs defined as ‘the average maintenance dose of a drug when used in its major indication in adults’ [104]. 2011 Defined Daily Doses (DDDs) were used for the study. This is in line with International recommendations for conducting drug utilisation and expenditure comparisons between countries [5,7,11,12,32,104]. Population figures for the Republic of Srpska were taken from published sources [12,13,101].

Reimbursed expenditure was used as the perspective is from a health insurance viewpoint. In addition, comprehensive and robust data on drug utilization is available in the Republic only via HIF. There has been no allowance for inflation as we wanted to compute the actual influence of the various policies in the Republic of Srpska on reimbursed prices/ DDD over time, as well as compare with other European countries. In addition, the tendency among European authorities is to cut prices for both patented drugs and generics when pharmaceutical expenditure is rising more rapidly than agreed budgets [2,4,7,8,18]. The practice of only using reimbursed expenditure, and making no allowance for inflation, mirrors previous publications [1,24,5,7-11]. One of the main reasons for adopting this practice regarding inflation is that pricing policies for generics in Europe are principally based on pre-patent loss prices [1,2,4,7,10].

Expenditure/DDD was initially calculated in local currency (convertible mark or BAM) before converting to Euros to enhance comparisons between countries [4,5,7,11,105]. The exchange rate for BAM  was taken from the The Central Bank of Bosnia and Herzegovina, i.e. €1 =1.955 [106]. The convertible mark (BAM) was established by the Dayton Agreement, and replaced the Bosnia and Herzegovina dinar (​http:​/​​/​en.wikipedia.org​/​wiki​/​Bosnia_and_Herzegovina_dinar" \o "Bosnia and Herzegovina dinar​) (BHD). It was principally pegged to the German mark (hence 'mark' in its name), but switched to being pegged to the Euro when Germany adopted the Euro in 2002. Since then the convertible mark has used the same fixed exchange rate to Euro (​http:​/​​/​en.wikipedia.org​/​wiki​/​Euro" \o "Euro​).

Reimbursed expenditure/ DDD for generic omeprazole, simvastatin and ACEIs, as well as differences over time, from other European countries and regions, were principally based on previous publications supplemented with personal communications (Brian Godman) where needed.

The number of generics on the market was also documented to asses whether this makes a difference to potential prices for generics.

A narrative review of the ongoing supply and demand side measures was undertaken by one of the co-authors (Brian Godman), based on feedback from co-authors from the Ministry of Health and Social Welfare in view of the paucity of peer-reviewed papers on pharmaceutical policy in the Republic of Srpska. The demand side measures during the study period were collated under the “4E” methodology, i.e. Education, Engineering, Economics and Enforcement – in line with previous publications [5, 7-11,17,19-21]. 

No confidence limits were included for expenditure and other calculations since all patients in the HIF database were included in the study. No sophisticated analyses such as time series analyses, mulivariate analysis or regression lines were perfomed. This is recognition of the many different supply and demand side initiatives introduced during the study period, e.g. Table 1, alongside variations in the formulary, treatment guidelines and reimbursement lists over time. 

Results

	PPIs

Recent supply and demand side measures (in addition to Table 1) included:
	Before 2008 (May) – the only reimbursed drug for acid-related stomach disorders (A02) was ranitidine, which is still on List A.
	2008 (May) - PPIs included for the first time in the List B (esomeprazole October 2008). List B in view of the anticipated financial impact following its listing if included in List A; however, HIF wished patients to have access to a number of PPIs.
	Not all doses of PPIs reimbursed, e.g. for omeprazole only the 20 mg tablet was reimbursed and for lansoprazole only the 30 mg tablet was reimbursed
	No other additional demand side measures

There was a 3.3 fold increase in the utilisation of PPIs once they were included in List B rising from 1.81 DDDs/ TID in 2008 to 5.96 DDDs/ TID in 2010, with omeprazole dominating prescribing (Figure 1). Generic versions of each PPI were available from 2008 to 2010.



Figure 1 – DDD/ TIDs PPIs since reimbursement (2008)



There was decreasing expenditure/ DDD for each PPI between 2008 and 2010 (Figure 2). However, the greater increase in utilisation of pantoprazole, lansoprazole and esomeprazole at a higher expenditure/ DDD than omeprazole (Figure 2) increased overall expenditure by 3.15 fold from €98.4/ 1000 inhabitants in 2008 to €310.3 in 2010. 

Figure 2 – Expenditure/ DDD (€) for PPIs 2008 to 2010

 

	Statins

Recent supply and demand side measures (in addition to the general measures discussed earlier) included:
	2002 (March) – statins were reimbursed for the first time
	2003 (February) – statins were delisted due to the financial impact
	2004 (June) – statins were reimbursed again, with 30% co-payment of the reference price (each manufacturer’s price)
	2006 – reference price of all reimbursed drugs set as the median wholesale price of the molecule, i.e. effectively a price cut
	2008 (May) – statins were switched to List B, with 50% co-payment of the reference price (the lowest molecule price). Alongside this, statins were restricted to specific diseases and conditions defined by IDC-10 as secondary prevention of coronary disease (I20-I25), diabetes mellitus with hypercholesterolemia (E10-E11) and chronic kidney insufficiency (N18), and organ transplantation (Z24) with hypercholesterolemia

These reforms resulted in greater than 19 fold increase in statin utilisation between 2004 to 2010, i.e. from 0.453 DDD/ TID in 2004 (when relisted) to 8.79 in 2010. This has been driven in recent years by greater utilisation of atorvastatin, with utilisation of simvastatin remaining stable (Figure 3). Generic simvastatin was available from 2004, with generic atorvastatin available and reimbursed from 2006.

Figure 3 – Utilisation of statins 2004 to 2010


NB From 2006 onwards no utilisation of fluvastatin in the Republic (very limited utilisation before this)

There was a 75% reduction in expenditure/ DDD for simvastatin in 2010 versus 2004 levels, coupled with a 82% reduction for atorvastatin (Table 2). This limited the increase in reimbursed expenditure for the statins to 4.1 fold in 2010 vs. 2004 (€380.1/ 1000 inhabitants in 2010 vs. €92.2 in 2004).

Table 2 – Expenditure/ DDD for the two major statins 2004 to 2010 (€)



	ACEIs/ ARBs

Recent supply and demand side measures (in addition to the general measures discussed earlier) included:

	ACEIs
o	2004 - systematic approach to the reimbursement of all ACEIs, single and in combination, with all ACEIs seen as therapeutically equivalent and the greater number enhancing patient choice. Patients subject to a 50% co-payment of the current reference price 
o	2006 - reference price of all reimbursed drugs set as the median wholesale price for each molecule, i.e. effectively a price cut
o	2008 (May) - some ACEIs were switched to List B  i.e. captopril and combinations of cilazapril and lisinopril with a diuretic, with 50% co-payment of the reference price; whilst others remaining on List A 
	ARBs
o	2009 (March) – losartan and losartan combined with a diuretic reimbursed for the first time and included in List B, subject to a 50 % co-payment
o	Not all doses reimbursed  e.g. losartan with a diuretic only the 50 mg tablet
o	Prescribing restricted to second line, i.e. patients experiencing unwanted side-effects with ACEIs and only upon specialist recommendation 

There was greater utilisation of renin-angiotensin inhibiting drugs in the Republic of Srpska than seen for the statins, with utilisation of ACEIs driven by increased use of enalapril, ramipril and captopril (Figure 4). There was also growing utilisation of ACEIs in combination, with a 25 fold increase in 2010 vs. 2003 (57.14 DDD/ TID vs. 2.29 DDD/ TID). Overall, the combined utilisation of renin-angiotensin inhibiting drugs (ACEIs and ARBs) grew 6.3 fold during the study period, rising from  27.37 DDD/ TID in 2003 to 171.16 in 2010 (Figure 4). 

Figure 4 – Utilisation of ACEIs and ARBs 2003 to 2010



There was a 39% reduction in expenditure/ DDD for ACEIs in 2010 vs. 2003 levels, particularly enalapril (-36%) and captopril (-61%), combined with a 42% reduction in expenditure/ DDD for the ACEIs in combination with diuretics (Table 3). This limited the increase in reimbursed expenditure for the combined renin-angitensin inhibitor drugs to seven fold from 2003 to 2010, despite an appreciable increase in the utilisation of ACEIs in combination at considerably higher expenditure/ DDD than the single agents (Table 2). Combined reimbursed expenditure for the renin-angiotensin inhibiting products was 709€/1000 inhabitants in 2003, rising to 5220€/1000 inhabitants in 2010.

Table 3 – Expenditure/ DDD (€) of selected ACEIs and ARBs 2003 to 2010


HTZD = Hydrochlorothiazide

	Generic prices and the number generics

Table 4 contains a comparison of reimbursed expenditure/ DDD for omeprazole, simvastatin and enalapril, as well as combined ACEIs, among selected European countries and regions with varying population sizes including the Republic of Srpska.

Table 4 – Expenditure/ DDD for generic omeprazole, simvastatin (2010 DDDs), enalapril and all ACEIs in 2007 in Euros unless stated [4,7,11,20,21,25,31,37,49, Brian Godman personal communication] 

NB. Abbreviations refer to EU countries. AT and DE = total expenditure; ES = Catalonia. Currency conversions at 2007 Bank rates. Molecules in the Republic of Srpska contain both generics and originators; however, this is typically the generic with reference pricing based on the lowest price available from 2008. Data is only available up to 2007 for the majority of European countries and only goes back to 2008 in the Republic of Srpska for some drugs. Low expenditure/ DDD for omeprazole when reimbursed limits opportunities for further reduction (Figure 2)

There were also similar percentage reductions in expenditure/ DDD over time for the statins and ACEIs (enalapril) in the Republic of Srpska compared with other European countries, which take account differences in VAT and pharmacy remuneration rates as well as fluctuations in currencies versus the Euro [4,11,19,31,33]:
	Generic simvastatin – Price reductions in expenditure/ DDD (2010 DDDs) of 53% to 97% for generic simvastatin in 2007 versus typically originator prices in 2001 in Austria, France, Germany, Italy, Lithuania (2009 vs. 2001 originator price), Portugal, Spain, Sweden and the UK. This compares with a 75% reduction for simvastatin in 2010 versus 2004 prices - typically generic simvastatin – in the Republic, and a 82% reduction for atorvastatin (pre-patent loss to reference pricing in 2010 based on the cheapest molecule) - Table 2
	ACEIs (enalapril)
o	Austria – ACEIs - 44% reduction for generic enalapril in 2007 vs. 2001 originator prices
o	Lithuania – 52% in 2009 vs. 2001 originator price (generic enalapril available since 1997)
o	Portugal - 40% reduction for generic enalapril in 2007 vs. 2000 originator prices
o	Scotland – 50% reduction for generic enalapril in 2007 vs. 2001 originator prices
o	Spain (Catalonia) 62% reduction for generic enalapril in 2007 versus 2003 originator prices
o	Sweden – 87% reduction generic enalapril and generic ramipril in 2007 vs. 2001 originator prices 
o	Republic of Srpska – 36% reduction for enalapril (generic and originator combined) in 2010 vs. 2003 (61% for captopril)

The number of generics available for pertinent molecules typically increased between 2004 and 2010; however, there was an appreciable variation in the absolute numbers for each molecule (Table 5).



Table 5 – Availability of multiple sourced products of the major entities in each class between 2004 and 2010.

Class	Drug	2004	2005	2006	2007	2008	2009	2010
PPIs	Omeprazole	na	na	na	na	6	6	10
	Pantoprazole	na	na	na	na	2	4	4
	Lanzoprazole	na	na	na	na	3	4	6
Statins	Simvastatin	3	3	5	6	8	8	9
	Atorvastatin	1	1	3	3	6	8	11
ACEIs, plain	Captopril	6	6	6	6	6	5	5
	Enalapril	7	8	8	7	8	9	10
	Lisinopril	3	4	6	6	8	9	8
	Quinapril, HTZD	1	1	1	1	1	1	1
	Enalapril, HTZD	1	1	2	2	2	2	4
NB HTZD-Hydrochlorothiazide, NA = Not available, 1 = just the originator available

Discussion

As expected, there was increased utilisation of each of the three drug classes over time, with the prescribing restrictions for the statins and the availability of ranitidine in List A, coupled with the PPIs only recently becoming reimbursed, limiting their overall utilisation versus Western European countries (Table 6). This is similar to the situation seen in other Central and Eastern European countries [11,31,33], confirming our expectations.

Table 6 - Ambulatory care utilisation of PPIs, statins and ACEIs/ ARBs in DDDs/TID among European countries in 2007 and the Republic of Srpska in 2007 (statins and ACEIs/ ARBs) and PPIs in 2009 (first full year of reimbursement) [4,7,11,20,21,25,31,49, Brian Godman Personal communication]


*Spain = Catalonia

Similarly, there was also considerably higher utilisation of ACEIs and ARBs in the Republic of Srpska (Figure 4) than for the PPIs and statins. This again mirrors the situation among Central and Eastern European countries [7, 31]. This may well be due to no prescribing restrictions for ACEIs compared with the statins coupled with hypertension seen as a serious disease, which is similar to the situation in Lithuania [31]. As a result, high utilisation of renin-angiotensin inhibitor drugs. However, this remains to be substantiated. In any event, the restrictions limiting the prescribing of ARBs to second line coupled with a 50% co-payment appear to be working in the Republic, with utilisation of losartan alone or in combination with a diuretic at only 1.7% of combined renin-angiotensin inhibitor drug utilisation in 2010. This mirrors the situation in Croatia with its strict prescribing restrictions for ARBs [7]. 

Table 6 also highlights the need to combine studies of drug utilisation with health policy reforms to help explain the different patterns seen both among different classes within and across countries (cross national comparisons). This builds on previous suggestions [107]. Otherwise, there may be a tendency to dismiss either very low or very high utilisation results.

The reduction in reimbursed expenditure/ DDD for the statins (simvastatin and atorvastatin), and the ACEIs alone and in combination (enalapril, captopril, combined ACEIs and ACEIs plus a diuretic), is in line with expectations. These reductions helped increase prescribing efficiency for the statins with only a 4.1 fold increase in reimbursed expenditure in 2010 vs. 2004 despite a 19 fold increase in utilisation (Figure 3). The situation for the PPIs is different with reductions in expenditure/ DDD for the various PPIs (Figure 2) offset by increasing utilisation of more expensive PPIs (Figures 1 and 2). Potential steps to address the situation for the PPIs could include instigating prescribing restrictions for esomeprazole and pantoprazole to second line (similar to the statins and the ARBs); alternatively prescribing targets for omeprazole and lanzoprazole versus all PPIs combined with physician financial incentives. Other potential approaches include reference pricing for the PPI cluster (A03BC – ATC Level 4) to the lowest price molecule. This is already starting to happen. Care will not be compromised with all PPIs seen as essentially similar [4,5,9-11,18-21] despite anecdotal claims by some physicians regarding their experiences with generic PPIs [34].

The same situation was also seen for the renin-angiotensin products with the reduction in expenditure/ DDD for the ACEIs alone or in combination offset by growing utilisation of appreciably more expensive ACEIs in combination with diuretics (Table 3). This is different to the situation in for instance Croatia and Scotland, where in Scotland just under 2% of total renin-angiotensin utilisation was for fixed dose combination (FDC) products in 2007 [7,25]. Whilst premium priced FDCs are recommended in the treatment guidelines for the management of hypertension in the Republic of Srpska, first line choices include single thiazide diuretics, beta blockers, calcium channel blockers or ACEIs [35 – Table 1]. These can be prescribed alone or combined to achieve the desired therapeutic effect before FDCs should be considered. This is also in line with recent European and health authority guidance encouraging patients to be treated with a range of different drug classes alone or combined before typically more expensive FDCs are prescribed [25,36,108]. Alongside this, there is also continuing controversy whether there is improved compliance in practice with FDCs versus taking single agents separately [37,38, 108,109]. Potential ways forward to enhance prescribing efficiency in the Republic could be introducing prescribing restrictions for FDC ACEIs whereby they should only be reimbursed once patients are stabilised on the respective single agents, which would be in line with current recommendations [35,36,108]. This would not compromise care, and would build on the prescribing restrictions that have already been successfully introduced to limit ARB utilisation. 

The percentage reductions in expenditure/ DDD for simvastatin and the various ACEIs (Tables 2 and 3), as well as absolute figures for expenditure/ DDD for generic omeprazole, simvastatin, enalapril and ACEIs, are encouraging and mirror those seen among a range of European countries (Table 6). As a result, providing further evidence to counter-act claims that countries with smaller populations have difficulties obtaining considerable price reductions for generics [29-31]. This is particularly important as resource pressures grow, with increasing urgency for countries to introduce additional reforms to further enhance their prescribing efficiency, which could include measures to obtain still lower prices for generics.  

Finally, it does appear that increasing the number of generic statins and ACEIs (Table 5) helps to lower the price of generics (Tables 2 and 3). This though remains to be seen with the PPIs (Figure 2). However, PPIs have only recently been reimbursed, and comparing reimbursed expenditure/ DDD for generic omeprazole among a range of European countries (Table 4) shows that the Republic of Srpska already has some of the lowest prices. Consequently, limited opportunities for further reductions.

We accept that there are limitations with this study. These include the fact that we have been unable to link diagnoses with patients, or to investigate current doses among patients. In addition, as previously mentioned, we have not been able to perform any time series analyses due to the multiple demand and supply side reforms instigated during the study period in the Republic of Srpska. This mirrors previous publications [5,7,10,11,19-21,31,38]. 

However, we hope we have demonstrated that countries with small populations can successfully introduce a range of measures to improve prescribing efficiency including measures to obtain appreciable price reductions for generics over time, even among classes with low utilisation compared with Western European countries. Successful measures in the Republic of Srpska to obtain low prices for generics appear to be reference pricing for the molecule based on the current lowest price coupled with encouragement of INN prescribing, substitution, and pharmacists professionally obliged to offer patients the cheapest product when multiple sourced products become available. Prices should be further lowered by the instigation of e-prescribing aiding INN prescribing. 

We believe we have also demonstrated that prescribing restrictions can limit the utilisation of drugs within a class as seen with the low utilisation of ARBs versus ACEIs. This builds on the successful introduction of prescribing restrictions for ARBs in Austria and Croatia [7], and for patent protected statins in Austria, Finland and Norway [10,21,22]. Finally, we believe we have also shown how the utilisation of PPIs can be restricted, especially with growing concerns about their long term safety [39-44], mirroring the situation in other Central and Eastern European countries.

In conclusion, we believe we have given hope to countries with smaller populations as they continually strive to enhance prescribing efficiencies through additional measures and reforms. Further planned measures over the coming years include potentially prescribing restrictions for ACEI combinations as well as greater clustering of classes where the products are seen as essentially similar such as the PPIs. Within these, reference prices based on the price of the lowest cost molecule. Efficiencies will be helped by envisaged further reductions in prices with the implementation of e-prescribing aided by INN prescribing. 

Key points

	Multiple demand- and supply-side measures have been introduced in the Republic of Srpska in recent years despite the small size of the country. These include measures to lower the price of generics including patients required to pay the difference for a more expensive molecule than the current referenced molecule, and pharmacists allowed to dispense a generic in place of an originator. 

	Multiple demand-side measures include prescribing guidelines and formularies, physicians encouraged through financial measures to enhance their prescribing efficiency and prescribing restrictions. The latter enforced through close monitoring of the prescriptions.

	These measures helped reduce expenditure/ DDD for various PPIs, statins and ACEIs by up to 82% in 2010 versus 2004 levels, demonstrating again that countries with small populations can obtain low prices for genrics despite the rhetoric. As a result, appreciably increase prescribing efficiency for the statins. 

	Prescribing efficiency for the PPIs was affected by increased use of esomeprazole at a higher exenditure/ DDD than generic omeprazole. Similarly, prescribing efficiency for the renin-angiotensin inhibitors was affected by increased utilisation of premium priced FDCs

	Consequently, further reforms are planned including increasing the number of reference price classes as well as potentially prescibing restrictions for more expensive PPIs and FDCs. This should not compromise care with all PPIs seen as essentially similar and the ongoing debate about the value of FDCs for the management of hypertension compared with less expensive single agents combined
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